1 published article · Updated continuously
28 trials tracked for Hyperphosphatemia: 19 in phase 3 or 4 and 8 with published results. The most-cited published study has 89 citations.
Showing the 28 most-cited and recently-updated of 28 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Several phosphate binders have demonstrated efficacy in managing serum phosphorus (s-P) levels. Tenapanor showed significant reductions in s-P levels from baseline at week 4 (p=0.0004) and a significant s-P response at week 4 (p=0.0097) 5. During a placebo-controlled randomized withdrawal period, Tenapanor was associated with significant increases in s-P levels in both the responder and ITT populations (p<0.0001 and p=0.0020, respectively) 6. Additionally, Tenapanor showed a significant placebo-adjusted increase in serum phosphate during a withdrawal period (p=0.01) and a significant reduction in serum phosphate during an 8-week treatment period (p<0.001) 7.
Ferric citrate was shown to significantly reduce serum phosphorus from baseline to the end of treatment (p<0.0001) 14. In a multi-arm study, ferric citrate was associated with a significant reduction in mean serum phosphorus from baseline to the end of the assessment period (p<0.0001) 13. Other agents, such as PA21, were associated with a significant reduction in mean serum phosphorus concentrations at the end of treatment (p=0.020) 9.
Clinical trials for MCI-196 were conducted to evaluate its effects on serum levels, including a reported percent change in serum LDL-cholesterol 17.
AI synthesis of 9 cited trials, updated Sep 3, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
